Results 11 to 20 of about 22 (22)

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 2, Page 99-106, April 2023., 2023
Background – A rebound of pruritus occasionally occurs after oclacitinib dose reduction in dogs with atopic dermatitis (AD). Objectives – To determine whether an initial 4‐day course of prednisolone decreases the probability of a pruritus rebound after reducing the frequency of oclacitinib administration.
Thierry Olivry, Viktorija Lokianskiene, Alejandro Blanco, Pablo Del Mestre, Kerstin Bergvall, Luc Beco   +5 more
wiley   +1 more source

A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client‐owned dogs with allergic dermatitis

Veterinary Dermatology, Volume 32, Issue 5, Page 477-e131, October 2021., 2021
Background – Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. Hypothesis/Objectives – To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.
Leen Van Brussel, Hilde Moyaert, Monica Escalada, Sean P. Mahabir, Michael R. Stegemann   +4 more
wiley   +1 more source

Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double‐blinded, placebo‐controlled trial

Veterinary Dermatology, Volume 32, Issue 2, Page 119-e25, April 2021., 2021
Background – Oclacitinib is an effective systemic therapy for dogs with atopic dermatitis (AD). Few studies have evaluated concurrent topical treatment with oclacitinib in dogs. Objectives – To evaluate the efficacy and safety of combination therapy of oclacitinib and 0.0584% hydrocortisone aceponate (HCA) spray in dogs with AD.
Junko Takahashi, Satoko Kanda, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Shoko Momiyama, Satoshi Nishiyama, Tomoki Motegi, Keita Iyori   +9 more
wiley   +1 more source

Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach

Veterinary Dermatology, Volume 36, Issue 4, Page 443-452, August 2025.
Background – Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD). Objective – To assess the anti‐inflammatory agent‐sparing effect over 1 year of immunotherapy using pullulan‐conjugated recombinant Der f 2 (rDf2‐P). Conclusions and Clinical Relevance – Der f 2‐P immunotherapy can lead to a rapid reduction in anti‐
Masahiko Nagata, Jin Kozakai, Aya Yoshida, Kana Kameyama, Hiromi Oboso, Hisanori Muto, Shoji Ogino, Toshihiro Tsukui   +7 more
wiley   +1 more source

Meta-type analysis of dopaminergic effects on gene expression in the neuroendocrine brain of female goldfish. [PDF]

Front Endocrinol (Lausanne), 2012
Popesku JT, Martyniuk CJ, Trudeau VL.
europepmc   +1 more source

Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. [PDF]

J Exp Med, 2005
Dias S, Silva H, Cumano A, Vieira P.
europepmc   +1 more source

Scapuloperoneal atrophy with sensory involvement: Davidenkow's syndrome. [PDF]

J Neurol Neurosurg Psychiatry, 1975
Schwartz MS, Swash M.
europepmc   +1 more source

Electrophysiological study of amyotrophy associated with acute asthma (asthmatic amyotrophy). [PDF]

J Neurol Neurosurg Psychiatry, 1975
Danta G.
europepmc   +1 more source

(CA/TG) microsatellite sequences escape the inhibition of recombination by mismatch repair in Saccharomyces cerevisiae. [PDF]

Genetics, 2001
Gendrel CG, Dutreix M.
europepmc   +1 more source

Electromyography in nutritional osteomalacic myopathy. [PDF]

J Neurol Neurosurg Psychiatry, 1976
Irani PF.
europepmc   +1 more source